Aiosyn raised €2.4 million in September 2025 and entered into partnership with TNO

Nijmegen-based Aiosyn closed a funding round of €2.4 million in September 2025. The round was led by TNO Ventures and supplemented by contributions from Oost NL, LUMO Labs and Health Innovations. The company intended to use the funds to further develop and broaden the rollout of its AI software for digital pathology.

Aiosyn was founded in 2021 as a spin-off from the Computational Pathology Group of Radboudumc in Nijmegen. The company builds software that supports pathologists in assessing tissue samples, with a focus on more accurate diagnoses in cancer care. The round brought the total funding raised to approximately €4.4 million. Alongside the capital injection, Aiosyn announced a strategic partnership with TNO and an expansion of its existing collaboration with Pathomation, a provider of digital pathology integration software.

What the funding means for the company

Aiosyn intended to put the proceeds toward several concrete goals. The company planned to invest in a new generation of AI algorithms for clinical decision-making in cancer patients, and to expand its existing portfolio with new digital pathology biomarkers and analysis tools for preclinical imaging research.

At the time, its products included AI models for breast cancer grading and a quality control model for tissue preparations. Aiosyn Mitosis Breast, a product that assesses mitotic activity in breast cancer biopsies, held a CE marking. A kidney model was also part of the portfolio.

CEO and co-founder Patrick de Boer led the company together with Jeroen van der Laak as chief scientific officer, Wouter Bulten as chief operating and product officer, and David Tellez as chief technology officer. The combination of an academic background from Radboudumc and commercial growth ambitions was typical of the company's positioning.

Partnership with TNO: mutual knowledge exchange

The partnership with TNO was substantive in nature for both parties. Aiosyn gained access to TNO's research facilities and network for clinical validation, which was intended to shorten the path to market readiness for new software modules. TNO, in turn, used Aiosyn's AI expertise to strengthen its own position in preclinical contract research services.

Hans Boumans, director of TNO Ventures, was quoted in the announcement as viewing Aiosyn as an example of the kind of innovation TNO aims to help scale. TNO Ventures, the investment arm of the Dutch research organisation, also acted as lead investor in the round, giving the collaboration both a financial and a strategic dimension.

The combination of an investment from TNO Ventures and an operational partnership with TNO itself was notable. It gave Aiosyn both capital and direct access to the knowledge and infrastructure of one of the larger technology partners in the Netherlands.

Expansion of collaboration with Pathomation

In addition to the TNO partnership, Aiosyn expanded its existing collaboration with Pathomation. Pathomation supplies software that allows laboratories and hospitals to manage digital pathology images and integrate them into existing workflows. The expansion focused on embedding Aiosyn's AI analyses more deeply in that environment, so that pathologists could consult the results directly within their own working environment.

Specific details about the technical integration or commercial arrangements with Pathomation are not known based on the available information. The announcement was made around 9 and 10 September 2025.

Digital pathology as a growing segment

Aiosyn operates in a segment that is gaining importance in the Netherlands and beyond. Hospitals and laboratories are increasingly switching to digital pathology workflows, in which physical glass slides are replaced by digitised images. This creates room for software companies that can deliver AI-driven analysis as a complement to the work of the pathologist.

Regional investors such as Oost NL and early-stage fund LUMO Labs were involved, underlining the company's roots in Nijmegen. The presence of Radboudumc as academic background and the ecosystem around the Health Valley region in Gelderland also play a role.

For other medtech and AI healthcare startups in the Netherlands, Aiosyn's round illustrates how an academic spin-off can grow through regional and sector-specific investors. The involvement of a major knowledge institution as both investor and strategic partner is a model that is increasingly appearing in the Dutch startup landscape beyond healthcare as well.

Correction 15 October 2026: an earlier version of this article presented this news as recent. It was announced on 9 September 2025.